Audit: QRS - Vitamin D for Health & Longevity
Audit conducted on 11/08/2026 12:17 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 407/409/417, time-to-effect to lines 168/421/473, benefit and risk tiers to the ER Expected Benefits and Potential Risks & Side Effects headings, gates to lines 340–379, monitoring to the ER table at lines 511–518 and cadence at line 507. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No mapped ER section is empty and no cautious hedge is dropped; at-a-glance mirrors the ER Conclusion wording (“have not shown fewer fractures, less cancer, or longer life”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “pushing levels higher raises calcium without further gain” preserves the ER’s “offering nothing further”; contraindication qualifiers (“without nephrology supervision”, “unless urinary calcium is monitored”) are carried intact. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from “Populations who should avoid Vitamin D”; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor appears in a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, expert names, NCT identifiers, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, evidence-first register carried over from the ER, including the ER’s own split framing of low versus adequate baseline levels. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds throughout, presented without alarmism or promotion. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Doses and targets are stated as observed practice, not issued as instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; no “should”, “must”, “recommend”, “advise”, or “consider” anywhere in the rendered text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | All cells are declarative statements of ER content. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns occur in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms appear only where they are the fact itself (marker names, drug classes, contraindication states); the at-a-glance is jargon-free. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, tier, and table cell is a bare fact with the ER’s explanations, magnitudes, and mechanisms stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search for “you”/”your”/”yours”: no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes willingness to test 25(OH)D, calcium, PTH, and urinary calcium and to titrate a dose. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | An eight-marker monitoring panel with a retest cadence assumes exactly this audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No population-level messaging or simplified consumer advice. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance foregrounds the baseline-level split and the U-shaped risk curve, which is the decision-relevant distinction for an optimizing reader. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“hypercalcemia”, “nephrolithiasis”, “albumin-corrected”); the at-a-glance phrase “broken bones” is the ER Conclusion’s own wording carried verbatim (ER line 557). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate titles, tier labels, and the Marker/Target/Why column headers match [qrs_template] character for character. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# spans are instantiated as marker_1..8_* and qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three <span website="..."> elements (evidence_review, audit, full_review) and all surrounding markup are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard maintenance dose”, “Correcting documented deficiency”, and “Form” are the ER Therapeutic Protocol bold labels verbatim (ER lines 407, 409, 417). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels use the ER’s own terms from line 473 (“non-skeletal endpoints”, “Blood levels”, deficiency symptoms); marker names are the ER biomarker-table names verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-file scan of the emoji code ranges returns no matches; the ER’s tier emoji are not carried over. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Single sheet, no second-page content; every section is condensed from the ER (magnitudes, mechanisms, and the monitoring table’s Context/Notes column all dropped), 706 rendered words total. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the rendered body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly so because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: vitamin_d_2026-0811-0953_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0811-1204. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: vitamin_d_2026-0811-0953_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine values are trimmed; quoting is used only where YAML requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Vitamin D for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Vitamin D for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/11/2026”, the MM/DD/YYYY form of 2026-0811-1204. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion lines 553 and 557 into the deficient/adequate split plus the dosing-pattern and ceiling caveats. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Bone-disease repair → ER line 553; null trials in adequate adults → line 553; tolerability and bolus harm → line 557; “without further gain” → line 557. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “blood levels”, “bone disease”, “calcium”, “broken bones” are all lay terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No ratios, confidence intervals, or percentages. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from “Populations who should avoid Vitamin D” (ER lines 374–379). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER contraindications are present, in ER order, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the stop_items span (lines 542–547). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationale “where extrarenal activation escapes feedback control” is stripped; no item carries a trailing dash clause. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “serum calcium above 10.5 mg/dL”, “stage 4–5 (eGFR below 30 mL/min/1.73 m²)”, and “unless urinary calcium is monitored” are all retained; only the ER’s lay glosses are trimmed. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six such populations and the section is correctly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All sixteen items map one-to-one to the ER bullets at lines 340–370. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All sixteen ER interaction bullets are represented; none duplicates any of the six contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Sixteen <li> elements inside the caution_items span (lines 555–570). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every item is reduced to the agent or class name; the ER’s monitoring instructions and mechanisms (e.g., “Serum calcium is typically checked 4–8 weeks after…”) are all stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named example drug is retained (hydrochlorothiazide/chlorthalidone/indapamide, phenytoin/phenobarbital/carbamazepine, prednisone/dexamethasone, atorvastatin/simvastatin, orlistat/mineral oil/activated charcoal, cholestyramine/colesevelam, paricalcitol/alfacalcidol/doxercalciferol, MK-4/MK-7). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names sixteen such interactions and the section is correctly populated, not empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol bullets at lines 407, 409, and 417. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Maintenance dose, deficiency correction, and form are the three decision-bearing bullets; the remaining ER bullets are commentary on approach, timing, and modifiers. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-derived content, including the 50,000 IU weekly alternative and the D3-versus-D2 rationale. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Deficiency symptoms, non-skeletal endpoints, and blood-level plateau are exactly the three horizons in the ER’s “Time to effect” bullet (line 473). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High-tier benefit (deficiency correction) → Medium/Low-tier trial endpoints → pharmacokinetic plateau. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 3–6 months / 3–5 years / 8–12 weeks with ER-sourced sub-lines (ER lines 168, 421, 473). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every entry is an ER Expected Benefits sub-heading. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at the ER’s own tier assignments (2 high, 3 medium, 4 low, 2 speculative). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; all Magnitude: lines, hazard ratios, and confidence intervals are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any benefits span; the ER’s “⚠️ Conflicted” markers are also removed. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every entry is an ER Potential Risks & Side Effects sub-heading. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at the ER’s own tier assignments (2 per tier). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the 1.54/1.64 risk ratios, the 66.9% versus 47.9% falls figures, and all mechanisms are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows come from the ER Monitoring Protocol & Defining Success table (lines 511–518). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers are present with their optimal ranges and “why” text verbatim: 25(OH)D, serum calcium, PTH, 24-hour urinary calcium, phosphate, RBC magnesium, eGFR, alkaline phosphatase. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 701 carries the 12-week retest, annual stable-dose, and twice-yearly conditions from ER line 507. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s “Qualitative markers worth tracking” list (lines 522–527). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six are present: proximal muscle strength, diffuse bone/muscle aching, respiratory infections, energy and seasonal mood, balance confidence, and new hypercalcemia symptoms. |
Issues 11/08/2026 12:17
Pass rate 100.00%. No issues found.
Issues 11/08/2026 12:09
- 9.2 — Four ER interactions omitted: [caution_items] (QRS lines 554-567) lists 12 of the ER’s 16 interaction bullets; ketoconazole and other azole antifungals, statins, over-the-counter bile acid sequestrants, and ultraviolet exposure and tanning beds are absent.
Fixes 11/08/2026 12:09
- 9.2 — Missing ER interactions added: Added the four omitted ER interaction bullets to [caution_items] in ER order — “Ketoconazole and other azole antifungals”, “Statins (atorvastatin, simvastatin)”, “Over-the-counter bile acid sequestrants (cholestyramine, colesevelam)”, and “Ultraviolet exposure and tanning beds” — bringing the gate to all 16 ER interactions.